Torsten Hoffman
Chief Operating Officer
ReSearch Pharmaceutical Service
Singapore
Biography
Silence Therapeutics, a company focused on developing medicines through the body’s natural mechanism of RNA interference, has appointed a new Chief Operating Officer. The position has been filled by Torsten Hoffman, who begins working in the role immediately.
Research Interest
Prior to Silence, Hoffman served as Chief Scientific Officer and Managing Director at Proteros for close to two years. He began his career at Roche and remained with the company for 15 years, beginning as Laboratory Head before moving up to become Head of Roche’s post-doctoral fellowship program.
